On 1 September, ImmunoBrain Checkpoint, a biopharmaceutical company developing novel disease-modifying immune therapies to combat neurodegenerative diseases, has been awarded a grant from the Alzheimer's Association’s under the 2020 Part the Cloud-Gates Partnership Grant Program. This USD 1 million award will support the company’s upcoming Phase I trial of IBC-Ab002 in Alzheimer’s disease (AD).
IBC-Ab002 is an antibody developed by ImmunoBrain Checkpoint, targeting to enhance the immune system and induce brain repair processes in people with AD. The company’s technology is based on studies by Professor Michal Schwartz at the Weizmann Institute of Science (Rehovot, Israel), who is now the company’s chief scientist. She pioneered the idea that the brain engages in a life-long healthy dialogue with the immune system for its maintenance and repair, and that this communication is compromised in aging and AD.